Synthetic-user startup Simile has closed a $200 million Series B round at a $2 billion valuation, just five months after emerging from stealth with a $100 million Series A led by Index Ventures, the company announced on July 30, 2026.
The Series B was led by Greenoaks, with participation from Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventures. CVS Health is also listed as one of Simile’s marquee customers.
Simile was founded by Joon Sung Park, a Stanford PhD graduate whose dissertation included a project called “Smallville,” in which AI agents carried on simulated human lives — including holding parties. The company offers simulated users for applications in marketing and product research, and has stated a mission of simulating “all eight billion people on earth, accurately and honestly.”
The rapid fundraising trajectory places Simile among a growing number of AI startups reaching unicorn status in compressed timeframes. The synthetic-user space has drawn broader venture capital interest: competitor Aaru raised a Series A in December at a $1 billion valuation.
The concept of simulating users for research has been compared to vibe coding for product mock-ups — a potentially useful tool for teams looking to model consumer behavior before committing to full-scale research. However, the source notes that the unpredictability of human decision-making, driven by both emotion and reason, is precisely why traditional market research exists, suggesting simulated users may complement rather than replace conventional methods.
Source: TechCrunch